Global Injectable Drug Delivery Market Analysis, Trends and Forecast to 2024
©
Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024
The Global injectable drug delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
Segmentation:
By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma& Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa)
Drivers:
Some of the major factors driving the market for injectable drug delivery market, such as increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. Increasing prevalence of chronic diseases, rising demand for self-injection devices, growth of the biologics, and technological advancements are the major factors driving the growth of the injectable drug delivery
market.GROWING GERIATRIC POPULATION
RISING CASES OF CHRONIC DISEASES
In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) across the globe has increased considerably over a period of time. The rapidly increasing aging population and the subsequent rise in chronic conditions are major factors driving the demand forself-injection devices and cost of healthcare.
RISING DEMAND OF SELF-INJECTION DEVICES
Self-injection devices are a combination of automatic injection systems with audio-visual guides for surgeries; this includes safety syringes and hidden needles, among others. It has also emerged as one of the fastest growing areas for unit dose medication in order to minimize drug waste and increase product lifespan.
GROWTH OF BIOLOGICS MARKET
The biologics market is considered to be the fastest-growing sector of the pharmaceutical industry. Biologics are large molecules that require to be administered by injections given their size and profile. Biologics are medicines made from living cells through highly complex manufacturing processes used to prevent, treat, diagnose, or cure a variety of serious and chronic illnesses including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.
TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches in order to improve the convenience and ease of administration of parenteral therapeutics.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some of the major players operating in this market are
• Baxter International, Inc.
• Becton Dickinson and Company
• Gerresheimer AG
• Pfizer, Inc.
• Schott AG
• Alkermes Plc.
• Eli Lilly and Company
• Sandoz
• Terumo Corporation
• Teva Pharmaceuticals Industries Ltd.
• Bespak
• Antares Pharma
• Elcam Medical
• Haselmeier
• Mylan N.V.
• Novo Nordisk
• Owen Mumford Ltd
• Sanofi
• West Pharmaceutical Services, Inc
• Ypsomed Holding AG.
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPORTUNITIES
4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. REGULATORY HURDLES
4.3.4.3. STABILITY OF PRODUCTS
4.3.4.4. STERILITY OF INJECTIONS
4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABLITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTOINJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTOINJECTORS
6.3.2.1.2. PREFILLED AUTOINJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTOINJECTORS
6.3.2.2.2. MANUAL AUTOINJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTOINJECTORS
6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTOINJECTORS
6.3.2.4.2. DISPOSABLE AUTOINJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.2.3.1. REUSABLE PEN INJECTORS
6.3.2.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.4. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.3.1. COLLOIDAL DISPERSIONS
7.3.1.1. LIPOSOMES
7.3.1.2. NIOSOMES
7.3.1.3. POLYMERIC MIXED MICELLES
7.3.1.4. NANOPARICLES
7.3.1.4.1. NANOSUSPENSIONS
7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.3.1.4.3. SOLID LIPID NANOPARTICLES
7.3.2. MICROPARTICLES
7.3.2.1. MICROSPHERES
7.3.2.2. MICROCAPSULES
7.3.3. LONG ACTING INJECTION FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASE
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. OSTEOPOROSIS
8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALERGY TREATMENT
8.6.3. AESTHETIC TREATMENTS
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
12.1.1. NORTH AMERICA
12.1.1.1. U.S.
12.1.1.2. CANADA
12.1.1.3. MEXICO
12.1.2. EUROPE
12.1.2.1. GERMANY
12.1.2.2. FRANCE
12.1.2.3. U.K.
12.1.2.4. ITALY
12.1.2.5. SPAIN
12.1.2.6. RUSSIA
12.1.2.7. TURKEY
12.1.2.8. BELGIUM
12.1.2.9. NETHERLANDS
12.1.2.7. SWITZERLAND
12.1.2.8. REST OF EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.3.1. JAPAN
12.1.3.2. CHINA
12.1.3.3. SOUTH KOREA
12.1.3.4. INDIA
12.1.3.5. AUSTRALIA
12.1.3.6. SINGAPORE
12.1.3.7. THAILAND
12.1.3.8. MALAYSIA
12.1.3.9. INDONESIA
12.1.3.10. PHILIPPINES
12.1.3.11. REST OF APAC
12.1.4. LATIN AMERICA
12.1.4.1. BRAZIL
12.1.4.2. REST OF LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.1.5.1. SOUTH AFRICA
12.1.5.2. REST OF MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1. BAXTER INTERNATIONAL, INC.
14.1.1. OVERVIEW
14.1.2. SWOT ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. REVENUE ANALYSIS
14.1.5. ANALYSTS VIEW
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. OVERVIEW
14.2.2. SWOT ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. REVENUE ANALYSIS
14.2.5. ANALYSTS VIEW
14.3. GERRESHEIMER, AG
14.3.1. OVERVIEW
14.3.2. SWOT ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. REVENUE ANALYSIS
14.3.5. ANALYST VIEW
14.4. PFIZER, INC.
14.4.1. OVERVIEW
14.4.2. SWOT ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. REVENUE ANALYSIS
14.4.5. ANALYSTS VIEW
14.5. SCHOTT AG
14.5.1. OVERVIEW
14.5.2. SWOT ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. REVENUE ANALYSIS
14.5.5. ANALYSTS VIEW
14.6. ALKERMES PLC
14.6.1. OVERVIEW
14.6.2. SWOT ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. REVENUE ANALYSIS
14.6.5. ANALYSTS VIEW
14.7. ELI LILLY AND COMPANY
14.7.1. OVERVIEW
14.7.2. SWOT ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. REVENUE ANALYSIS
14.7.5. ANALYSTS VIEW
14.8. SANDOZ
14.8.1. OVERVIEW
14.8.2. SWOT ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. REVENUE ANALYSIS
14.8.5. ANALYSTS VIEW
14.9. TERUMO CORPORATION
14.9.1. OVERVIEW
14.9.2. SWOT ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. REVENUE ANALYSIS
14.9.5. ANALYSTS VIEW
14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.10.1. OVERVIEW
14.10.2. SWOT ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. REVENUE ANALYSIS
14.10.5. ANALYSTS VIEW
15. APPENDIX
15.1. RELATED REPORTS
15.2. CUSTOMIZABLE OPTIONS
15.3. SOURCE SHEET
15.4. BIBLIOGRAPHY
16. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
Global Hemostats Market- Trends and Forecast to 2024
Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/medical-devices/general-surgery-medical-devices/global-hemostats-market-trends-forecast-2024/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/
The Global injectable drug delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024.
Request for Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
Segmentation:
By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma& Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa)
Drivers:
Some of the major factors driving the market for injectable drug delivery market, such as increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. Increasing prevalence of chronic diseases, rising demand for self-injection devices, growth of the biologics, and technological advancements are the major factors driving the growth of the injectable drug delivery
market.GROWING GERIATRIC POPULATION
RISING CASES OF CHRONIC DISEASES
In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) across the globe has increased considerably over a period of time. The rapidly increasing aging population and the subsequent rise in chronic conditions are major factors driving the demand forself-injection devices and cost of healthcare.
RISING DEMAND OF SELF-INJECTION DEVICES
Self-injection devices are a combination of automatic injection systems with audio-visual guides for surgeries; this includes safety syringes and hidden needles, among others. It has also emerged as one of the fastest growing areas for unit dose medication in order to minimize drug waste and increase product lifespan.
GROWTH OF BIOLOGICS MARKET
The biologics market is considered to be the fastest-growing sector of the pharmaceutical industry. Biologics are large molecules that require to be administered by injections given their size and profile. Biologics are medicines made from living cells through highly complex manufacturing processes used to prevent, treat, diagnose, or cure a variety of serious and chronic illnesses including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.
TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches in order to improve the convenience and ease of administration of parenteral therapeutics.
Browse Full Report with Details TOC @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
Based on geography, the market is segmented into five geographical regions:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.
Some of the major players operating in this market are
• Baxter International, Inc.
• Becton Dickinson and Company
• Gerresheimer AG
• Pfizer, Inc.
• Schott AG
• Alkermes Plc.
• Eli Lilly and Company
• Sandoz
• Terumo Corporation
• Teva Pharmaceuticals Industries Ltd.
• Bespak
• Antares Pharma
• Elcam Medical
• Haselmeier
• Mylan N.V.
• Novo Nordisk
• Owen Mumford Ltd
• Sanofi
• West Pharmaceutical Services, Inc
• Ypsomed Holding AG.
Inquiry before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market
Table Of Content:
1. INTRODUCTION
1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
2.2.6. PORTER’S FIVE FORCES MATRIX
2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES
4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
4.3.2. RESTRAINTS
4.3.3. OPPORTUNITIES
4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES
4.3.4. THREATS
4.3.4.1. PRODUCT RECALLS
4.3.4.2. REGULATORY HURDLES
4.3.4.3. STABILITY OF PRODUCTS
4.3.4.4. STERILITY OF INJECTIONS
4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE
5.1. OVERVIEW
5.2. INJECTABLE DRUG DELIVERY DEVICES
5.3. INJECTABLE DRUG DELIVERY FORMULATIONS
6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. CONVENTIONAL INJECTION DEVICES
6.2.1. BY MATERIAL
6.2.1.1. GLASS
6.2.1.2. PLASTIC
6.2.2. BY PRODUCT
6.2.2.1. EMPTY SYRINGES
6.2.2.2. PREFILLED SYRINGES
6.2.3. BY USABLITY
6.2.3.1. REUSABLE SYRINGES
6.2.3.2. DISPOSABLE SYRINGES
6.3. SELF INJECTION DEVICES
6.3.1. NEEDLE FREE INJECTORS
6.3.1.1. BY PRODUCT
6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS
6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS
6.3.1.2. BY TECHNOLOGY
6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS
6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS
6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS
6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS
6.3.1.3. BY USABILITY
6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS
6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS
6.3.2. AUTOINJECTORS
6.3.2.1. BY PRODUCT
6.3.2.1.1. EMPTY AUTOINJECTORS
6.3.2.1.2. PREFILLED AUTOINJECTORS
6.3.2.2. BY TECHNOLOGY
6.3.2.2.1. AUTOMATED AUTOINJECTORS
6.3.2.2.2. MANUAL AUTOINJECTORS
6.3.2.3. BY DESIGN
6.3.2.3.1. STANDARDIZED AUTOINJECTORS
6.3.2.3.2. CUSTOMIZED AUTOINJECTORS
6.3.2.4. BY USABILITY
6.3.2.4.1. REUSABLE AUTOINJECTORS
6.3.2.4.2. DISPOSABLE AUTOINJECTORS
6.3.3. PEN INJECTORS
6.3.3.1. BY PRODUCT
6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS
6.3.3.2. BY DESIGN
6.3.3.2.1. STANDARDIZED PEN INJECTORS
6.3.3.2.2. CUSTOMIZED PEN INJECTORS
6.3.3.3. BY USABILITY
6.3.2.3.1. REUSABLE PEN INJECTORS
6.3.2.3.2. DISPOSABLE PEN INJECTORS
6.3.4. WEARABLE INJECTORS
6.3.5. OTHER INJECTABLE DEVICES
7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE
7.1. OVERVIEW
7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.2.1. SOLUTIONS
7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.2.3. SUSPENSIONS
7.2.4. EMULSIONS
7.3. NOVEL DRUG DELIVERY FORMULATIONS
7.3.1. COLLOIDAL DISPERSIONS
7.3.1.1. LIPOSOMES
7.3.1.2. NIOSOMES
7.3.1.3. POLYMERIC MIXED MICELLES
7.3.1.4. NANOPARICLES
7.3.1.4.1. NANOSUSPENSIONS
7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS
7.3.1.4.3. SOLID LIPID NANOPARTICLES
7.3.2. MICROPARTICLES
7.3.2.1. MICROSPHERES
7.3.2.2. MICROCAPSULES
7.3.3. LONG ACTING INJECTION FORMULATIONS
8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS
8.1. OVERVIEW
8.2. AUTOIMMUNE DISEASES
8.2.1. RHEUMATOID ARTHRITIS
8.2.2. MULTIPLE SCLEROSIS
8.2.3. CHRON’S DISEASE
8.2.4. PSORIASIS
8.2.5. OTHER AUTOIMMUNE DISEASES
8.3. HORMONAL DISORDERS
8.3.1. DIABETES
8.3.2. ANEMIA
8.3.3. REPRODUCTIVE HEALTH DISEASE
8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. OSTEOPOROSIS
8.3.6. GROWTH HORMONE DEFICIENCY (GHD)
8.4. ORPHAN DISEASES
8.5. ONCOLOGY
8.6. OTHERS
8.6.1. PAIN MANAGEMENT
8.6.2. ALERGY TREATMENT
8.6.3. AESTHETIC TREATMENTS
8.6.4. HEPATITIS C
8.6.5. HEMOPHILIA
9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)
10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM
11. INJECTABLE DRUG DELIVERY MARKET, BY END USER
11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS
12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY
12.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
12.1.1. NORTH AMERICA
12.1.1.1. U.S.
12.1.1.2. CANADA
12.1.1.3. MEXICO
12.1.2. EUROPE
12.1.2.1. GERMANY
12.1.2.2. FRANCE
12.1.2.3. U.K.
12.1.2.4. ITALY
12.1.2.5. SPAIN
12.1.2.6. RUSSIA
12.1.2.7. TURKEY
12.1.2.8. BELGIUM
12.1.2.9. NETHERLANDS
12.1.2.7. SWITZERLAND
12.1.2.8. REST OF EUROPE
12.1.3. ASIA-PACIFIC (APAC)
12.1.3.1. JAPAN
12.1.3.2. CHINA
12.1.3.3. SOUTH KOREA
12.1.3.4. INDIA
12.1.3.5. AUSTRALIA
12.1.3.6. SINGAPORE
12.1.3.7. THAILAND
12.1.3.8. MALAYSIA
12.1.3.9. INDONESIA
12.1.3.10. PHILIPPINES
12.1.3.11. REST OF APAC
12.1.4. LATIN AMERICA
12.1.4.1. BRAZIL
12.1.4.2. REST OF LATIN AMERICA
12.1.5. MIDDLE EAST AND AFRICA
12.1.5.1. SOUTH AFRICA
12.1.5.2. REST OF MIDDLE EAST AND AFRICA
12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
13.7. MERGERS & ACQUISITIONS
13.8. NEW PRODUCT DEVELOPMENT & APPROVALS
13.9. EXPANSIONS
13.10. REGULATORY CHANGES
13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
14.1. BAXTER INTERNATIONAL, INC.
14.1.1. OVERVIEW
14.1.2. SWOT ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. REVENUE ANALYSIS
14.1.5. ANALYSTS VIEW
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. OVERVIEW
14.2.2. SWOT ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. REVENUE ANALYSIS
14.2.5. ANALYSTS VIEW
14.3. GERRESHEIMER, AG
14.3.1. OVERVIEW
14.3.2. SWOT ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. REVENUE ANALYSIS
14.3.5. ANALYST VIEW
14.4. PFIZER, INC.
14.4.1. OVERVIEW
14.4.2. SWOT ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. REVENUE ANALYSIS
14.4.5. ANALYSTS VIEW
14.5. SCHOTT AG
14.5.1. OVERVIEW
14.5.2. SWOT ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. REVENUE ANALYSIS
14.5.5. ANALYSTS VIEW
14.6. ALKERMES PLC
14.6.1. OVERVIEW
14.6.2. SWOT ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. REVENUE ANALYSIS
14.6.5. ANALYSTS VIEW
14.7. ELI LILLY AND COMPANY
14.7.1. OVERVIEW
14.7.2. SWOT ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. REVENUE ANALYSIS
14.7.5. ANALYSTS VIEW
14.8. SANDOZ
14.8.1. OVERVIEW
14.8.2. SWOT ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. REVENUE ANALYSIS
14.8.5. ANALYSTS VIEW
14.9. TERUMO CORPORATION
14.9.1. OVERVIEW
14.9.2. SWOT ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. REVENUE ANALYSIS
14.9.5. ANALYSTS VIEW
14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.10.1. OVERVIEW
14.10.2. SWOT ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. REVENUE ANALYSIS
14.10.5. ANALYSTS VIEW
15. APPENDIX
15.1. RELATED REPORTS
15.2. CUSTOMIZABLE OPTIONS
15.3. SOURCE SHEET
15.4. BIBLIOGRAPHY
16. ABOUT DATA BRIDGE MARKET RESEARCH
Related Report
Global Hemostats Market- Trends and Forecast to 2024
Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2024
http://databridgemarketresearch.com/reports/medical-devices/general-surgery-medical-devices/global-hemostats-market-trends-forecast-2024/
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Ankit Singh
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog http://databridgemarketresearch.com/blog/